XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Net loss $ (4,409) $ (7,544)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 497 442
Amortization of deferred financing costs and debt discount 105 219
Provision for expired inventory 326 340
Share-based compensation expense 143 199
Loss on asset disposal 22 2
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable (747) 335
Inventories 141 7
Other current assets 301 (65)
Other assets (24) 24
Accounts payable and accrued expenses (556) (484)
Deferred revenues 84 12
Long-term deferred rent (2) 0
Net cash used in operating activities (4,119) (4,827)
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (53) (5)
Net cash used in investing activities (53) (1,163)
Cash flows from financing activities:    
Principal payments on long-term obligations 0 (1,770)
Proceeds from sale of common stock, net (150) 1,435
Net cash used in financing activities (150) (335)
Effect of exchange rate changes on cash and cash equivalents 39 20
Net decrease in cash and cash equivalents (4,283) (6,305)
Cash, cash equivalents, and restricted cash at beginning of period 10,225 12,910
Cash, cash equivalents, and restricted cash at end of period 5,942 6,605
Cash paid during period for:    
Interest 311 384
Supplemental schedule of non-cash investing and financing activities:    
Conversion of preferred stock into common stock 4 0
Azaya Therapeutics, Inc. [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
In process research and development acquired from Azaya Therapeutics 0 1,686
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets 0 (1,158)
Supplemental schedule of non-cash investing and financing activities:    
Liabilities assumed in payment for assets acquired 0 279
Common stock issued in payment for the assets acquired $ 0 $ 2,311